Endometrial Genomic Profile in Endometrial Priming

Not Applicable

Completed

• Conditions: Genomic Human Endometrial Expression Profile

• Registration Number: NCT01778452
• Lead Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA

Brief Summary

The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

Detailed Description

We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone

* 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Study Timeline

• Study Start: 2009-11
• Primary Completion: 2012-10
• Study Completion: 2013-01
• Study First Submitted: 2013-01-25
• Study First Submitted QC: 2013-01-28
• Study First Posted: 2013-01-29
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-14
• Last Update Posted: 2013-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 6

Inclusion Criteria

• 6 egg healthy volunteer egg donors.
• Volunteers.
• 18-35 years old
• Healthy.
• BMI <28.

Exclusion Criteria

• • BMI > 28
• Smokers-

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
genetic endometrial human profile expression	Oocyte donors will be followed up for four to six months	implantation related genes profile expression

Trial Locations

Locations (1)

Ivi Valencia; 🇪🇸 Valencia, Spain